Zhejiang Cancer Hospital
🇨🇳China
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT05322499
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
The 90% Effective Flow of High Flow Nasal Oxygenation (HFNO) During Sedated Bronchoscopy
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT05298319
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT05290090
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Early Detection of Gastric Cancer Using Plasma Cell-free DNA Fragmentomics
- Conditions
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05269056
- Locations
- 🇨🇳
Zhejiang Cancer Hospital；Cancer hospital of the university of chinese academy of sciences, Hangzhou, Zhejiang, China
A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT05247619
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Retrospective Study of Brachytherapy
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05242861
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
H101 Combined With Camrelizumab for Recurrent Cervical Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT05234905
- Locations
- 🇨🇳
Jinhua Municipal Central Hospital Medical Group, Jinhua, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳Ningbo First Hospital, Ningbo, China
Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT05232552
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou,, Zhejiang, China
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT05228496
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
HFNC and Hypoxia/Desaturation During Radiofrequency Ablation Under Moderate Sedation: A Randomized Clinical Trial
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05212064
- Locations
- 🇨🇳
Zhejiang Cancer hospital, Hangzhou, Zhejiang, China
© Copyright 2024. All Rights Reserved by MedPath